Headlines about Corcept Therapeutics (NASDAQ:CORT) have trended somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Corcept Therapeutics earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.1283982750855 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the headlines that may have effected Accern’s scoring:
- 4 Biotech Stocks That Show Promise on Sustainable Growth (finance.yahoo.com)
- Walgreens Boots Alliance, Inc. (WBA) Attaining Market Attention on Technical Facts- Corcept Therapeutics … – Investing News Update (investingbizz.com)
- Corcept Therapeutics Incorporated (NASDAQ:CORT), The Goldman Sachs Group, Inc. (NYSE:GS)Buy or Sell? What … – Market Breaking Point (press release) (journalfinance.net)
- Consensus score reveals Hold position in Stock: Corcept Therapeutics Incorporated (CORT) – Street Observer (press release) (streetobserver.com)
- Reviewing Corcept Therapeutics (CORT) & Cambrex Corporation (CBM) (americanbankingnews.com)
Corcept Therapeutics (NASDAQ:CORT) opened at 17.81 on Friday. Corcept Therapeutics has a one year low of $5.77 and a one year high of $18.31. The stock has a market capitalization of $2.02 billion, a PE ratio of 88.61 and a beta of 2.07. The firm has a 50-day moving average of $15.21 and a 200 day moving average of $12.02.
Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.02. Corcept Therapeutics had a net margin of 22.28% and a return on equity of 51.45%. The business had revenue of $35.56 million for the quarter, compared to analysts’ expectations of $31.37 million. During the same period last year, the business earned $0.01 EPS. The company’s revenue was up 80.3% compared to the same quarter last year. On average, equities research analysts anticipate that Corcept Therapeutics will post $0.42 earnings per share for the current fiscal year.
Several research firms recently commented on CORT. Stifel Nicolaus began coverage on shares of Corcept Therapeutics in a research note on Thursday, August 31st. They set a “buy” rating and a $20.00 price objective on the stock. Ladenburg Thalmann Financial Services set a $20.00 price objective on shares of Corcept Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, July 18th. BidaskClub raised shares of Corcept Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. TheStreet raised shares of Corcept Therapeutics from a “c+” rating to a “b” rating in a research note on Monday, May 22nd. Finally, Piper Jaffray Companies set a $18.00 price objective on shares of Corcept Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and two have issued a strong buy rating to the company. Corcept Therapeutics has a consensus rating of “Buy” and an average target price of $16.17.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2017/09/17/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-corcept-therapeutics-cort-share-price.html.
In related news, Director David L. Mahoney sold 6,510 shares of Corcept Therapeutics stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $12.50, for a total value of $81,375.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David L. Mahoney sold 23,006 shares of Corcept Therapeutics stock in a transaction that occurred on Wednesday, July 19th. The stock was sold at an average price of $12.50, for a total transaction of $287,575.00. The disclosure for this sale can be found here. Insiders sold a total of 42,601 shares of company stock worth $532,513 over the last 90 days. Company insiders own 19.20% of the company’s stock.
About Corcept Therapeutics
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).
Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.